Clinical Trials · NCT06354660
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 537
- Start date
- Apr 2024
- Locations
- 48 sites, 4 countries
- Primary endpoint
- Change from Baseline in Hemoglobin A1c (HbA1c) (%)